Skip to main content
Andrew Seidman, MD, Oncology, New York, NY, Memorial Sloan Kettering Cancer Center

AndrewDSeidmanMD

Oncology New York, NY

Professor, Medicine, Weill Cornell Medical College

Overview of Dr. Seidman

Dr. Andrew Seidman is an oncologist in New York, NY and is affiliated with multiple hospitals in the area, including Memorial Sloan Kettering Cancer Center and NYC Health + Hospitals / Bellevue. He received his medical degree from Drexel University College of Medicine/Hahnemann University and has been in practice 37 years. Dr. Seidman accepts several types of health insurance, listed below. He is one of 463 doctors at Memorial Sloan Kettering Cancer Center and one of 61 doctors at NYC Health + Hospitals / Bellevue who specialize in Oncology. He has more than 100 publications and over 500 citings.

Education & Training

  • Memorial Sloan Kettering Cancer Center
    Memorial Sloan Kettering Cancer CenterFellowship, Hematology and Medical Oncology, 1989 - 1992
  • Pennsylvania Hospital of the University of Pennsylvania Health System
    Pennsylvania Hospital of the University of Pennsylvania Health SystemResidency, Internal Medicine, 1985 - 1988
  • Drexel University College of Medicine
    Drexel University College of MedicineClass of 1985

Certifications & Licensure

  • NY State Medical License
    NY State Medical License 1989 - 2026
  • NJ State Medical License
    NJ State Medical License 2020 - 2025
  • FL State Medical License
    FL State Medical License 2019 - 2021
  • PA State Medical License
    PA State Medical License 1986 - 1990
  • American Board of Internal Medicine Internal Medicine
  • American Board of Internal Medicine Medical Oncology

Clinical Trials

Publications & Presentations

PubMed

Authored Content

  • A Phase IIA Trial of Acupuncture to Reduce Chemotherapy-Induced Peripheral Neuropathy Severity During Neoadjuvant or Adjuvant Weekly Paclitaxel Chemotherapy in Breast Cancer PatientsAugust 2018

Press Mentions

  • Positive Results of CONTESSA, a Phase 3 Study of Tesetaxel in Patients with Metastatic Breast Cancer, Presented at the 2020 San Antonio Breast Cancer Symposium (SABCS)
    Positive Results of CONTESSA, a Phase 3 Study of Tesetaxel in Patients with Metastatic Breast Cancer, Presented at the 2020 San Antonio Breast Cancer Symposium (SABCS)December 11th, 2020
  • Odonate Therapeutics Announces Positive Top-Line Results from CONTESSA, a Phase 3 Study of Tesetaxel in Patients with Metastatic Breast Cancer
    Odonate Therapeutics Announces Positive Top-Line Results from CONTESSA, a Phase 3 Study of Tesetaxel in Patients with Metastatic Breast CancerAugust 24th, 2020
  • Selected Abstracts from the San Antonio Breast Cancer Symposium
    Selected Abstracts from the San Antonio Breast Cancer SymposiumFebruary 11th, 2019
  • Join now to see all

Hospital Affiliations

Insurance Accepted

  • Aetna Choice POS II
    Aetna HMO
    BCBS Blue Card PPO
    Blue Shield California PPO
    CIGNA HMO
    CIGNA Open Access
    CIGNA PPO
    Empire BCBS HMO
    Empire BCBS PPO
    First Health PPO
    GHI PPO
    Great West PPO
    Humana ChoiceCare Network PPO
    Multiplan PHCS PPO
    Multiplan PHCS PPO - Kaiser
    Multiplan PPO
    MVP Healthcare PPO
    Oxford Health Freedom
    Oxford Health Liberty
    QualCare HMO
    QualCare PPO
    United Healthcare - Direct Choice Plus POS
    United Healthcare - Direct Options PPO
    WEA Trust Preferred Provider Plan - Trust Pref
  • Please verify your coverage with the provider's office directly when scheduling an appointment